Sabadell Asset Management, S.A S.G.I.I.C Abb Vie Inc. Transaction History

Sabadell Asset Management, S.A S.G.I.I.C

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Jan 23, 2024	SELL	$134.21 - $153.93 $1.11 Million - $1.27 Million	-8,244 Closed	0 $0
Q1 2022 Jan 23, 2024	BUY	$131.98 - $163.75 $115,218 - $142,953	873 Added 11.84%	8,244 $1.43 Billion
Q4 2021 Jan 23, 2024	BUY	$107.43 - $135.93 $77,671 - $98,277	723 Added 10.88%	7,371 $984 Million
Q3 2021 Jan 23, 2024	SELL	$106.4 - $120.78 $3.54 Million - $4.02 Million	-33,295 Reduced 83.36%	6,648 $717 Million
Q2 2021 Jan 23, 2024	BUY	$105.21 - $117.21 $4.2 Million - $4.68 Million	39,943 New	39,943 $4.5 Billion

3,869

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $301B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Sabadell Asset Management, S.A S.G.I.I.C, based on Form 13F filings with the SEC.

Stay updated on Sabadell Asset Management, S.A S.G.I.I.C with notifications on news.